Allan Camaisa insider trades: Calidi Biotherapeutics (CLDI) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Allan reports to the SEC
Open-market buys and sales
2 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Dec 12, 2025 | CLDI | ↓ Sell | 850 | $1.46 | $1K | AJC Capital, LLC | Dec 16, 2025 (4d) |
| Dec 17, 2024 | CLDI | ↓ Sell | 10,000 | $1.62 | $16K | Direct | Dec 18, 2024 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Allan Camaisa's insider trades
Allan Camaisa is a director at Calidi Biotherapeutics (CLDI). Since Dec 17, 2024, Allan has reported no open-market purchases and 2 sales worth $17K on SEC Form 4. In the last 12 months: 1 sale ($1K).
Their filings also include grants and awards (3 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every CLDI insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.